News & views
Our collective understanding of mental health is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.
For media inquiries, contact us at firstname.lastname@example.org
March 08, 2022Our annual review 2021
In 2021 we we took a giant leap forward in our work to transform mental health care. Read about our progress.
February 24, 2022COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights
February 03, 2022GAMIAN-Europe’s Quality of Life project
We spoke to GAMIAN-Europe about their new guide on finding and achieving quality of life beyond a mental health condition.
January 24, 2022Meet Evie, a neuroscientist and BNA Scholar
To recognise the International Day of Education, Evie talked to us about neuroscience and her educational journey.
January 19, 2022Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression
January 04, 2022A New Year message to our community
January 04, 2022COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology
December 17, 2021COMPASS selected for addition to NASDAQ Biotechnology Index
December 16, 2021Our team’s highlights and reflections from 2021
"I’ve learnt that it’s important to try new things, even if they scare you."
December 16, 2021COMPASS Pathways announces changes in Executive Team
December 13, 2021COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study
December 06, 2021George and Ekaterina at Meet Delic 2021
Video courtesy of Meet Delic
December 03, 2021Michael Falvey joins COMPASS Pathways as Chief Financial Officer
December 01, 2021COMPASS Pathways announces further positive results from groundbreaking phase 2b trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
November 23, 2021COMPASS Pathways granted fifth US patent for crystalline psilocybin
November 09, 2021COMPASS Pathways announces positive topline results from groundbreaking phase 2b trial of investigational COMP360 psilocybin therapy for treatment-resistant depression
November 09, 2021COMPASS Pathways plc announces financial results and business highlights for the third quarter 2021
November 03, 2021COMPASS Pathways to launch phase 2 trial of COMP360 psilocybin therapy for post-traumatic stress disorder
October 22, 2021Our wellbeing programme at COMPASS
Anne Benedict, our Chief People Officer, talks about our approach to creating a workplace that supports mental health.
September 14, 2021COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs
September 10, 2021Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds
September 08, 2021Ecosia: the search engine that plants trees
We've partnered with Ecosia to fund tree-planting projects.
August 18, 2021Completing our phase IIb clinical trial
An infographic on this significant milestone.
August 13, 2021White Paper 2021
Our White Paper looks at the state of mental health care in the US, with a focus on treatment-resistant depression.
August 11, 2021COMPASS Pathways plc announces financial results and business highlights for the second quarter 2021
July 29, 2021Guy Goodwin joins COMPASS Pathways as Chief Medical Officer
July 21, 2021Danielle Schlosser joins COMPASS Pathways from Verily Life Sciences to lead clinical innovation and therapist training
July 05, 2021COMPASS Pathways joins forces with King’s College London and South London and Maudsley NHS Foundation Trust to accelerate psychedelic research and develop new models of mental health care in the UK
June 30, 2021COMPASS Pathways launches new podcast “Everyone has a story: talking about mental health”